Significance of HER2 expression in urinary bladder cancer: single institutional data | ||||
SECI Oncology Journal | ||||
Volume 10, Issue 3, July 2022, Page 136-145 | ||||
View on SCiNiTO | ||||
Abstract | ||||
Background: Targeted and immunotherapy got approval to treat locally advanced and/or metastatic urinary bladder (UB) cancer in specific situations. Human epidermal growth factor receptor 2 (HER2) expression is certified in UB cancer but with controversial results regarding the impact of targeted therapies on survival. This study explored expression of HER2 protein in UB cancer patients in our locality and its correlation with clinical outcomes. Methods: One hundred-thirty two samples of UB cancer collected and tested for HER2 receptor expression using immunohistochemistry (IHC) analysis. Together with patients medical records from 2012 through 2016 used analyze its significance with tumor characteristics and investigate its effect on DFS, PFS and OS. This work was conducted at Sohag University Hospital and Sohag Cancer Center. Data was analyzed using STATA intercooled version 16 for clinic-pathological associations. Results: HER2 expression was positive in 65% of samples; only pathological subtype had a significant association with HER expression intensity (p= 0.001). No significant association found between HER2 expression and other variables as regards age, tumor size, nodal spread or stage. As regards OS; HER2 positive expression associated with significant longer cumulative OS (p=0.006) and in multivariate Cox-regression analysis; it was the only factor associated with statistically significant longer OS (p=0.04; HR=0.43). No significant association found in the cumulative or Cox analysis for DFS and PFS (p= 0.79 and p= 0.08 respectively). Conclusion: in this work; HER2 expression was higher in bladder cancer cases especially in TCC. Also, patients with HER2 positive protein expression had a significant longer OS with probability and regression positive effect. No significant effect on DFS or PFS in the probability or Cox analysis of HER2 expression. However, these findings mandate larger prospective studies with anti-HER2 agents included in the management of these patients | ||||
Keywords | ||||
HER2 expression; Bladder Cancer | ||||
Supplementary Files
|
||||
Statistics Article View: 73 |
||||